Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: A case report

Journal of Chemotherapy

Volumn 21, Issue 3, 2009, Pages 367-368

  Belvisi, V ^a   Fabietti, P ^b   Del Borgo, C ^b   Marocco, R ^a   Di Vincenzo, E ^b   Soscia, F ^b   Mastroianni, Claudio M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Ospedale SM Goretti   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFEPIME; COTRIMOXAZOLE; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIGECYCLINE;

ADOLESCENT; ARTERY BYPASS; BIOAVAILABILITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DISK DIFFUSION; DRUG ACTIVITY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRACTURE REDUCTION; HOSPITAL INFECTION; HUMAN; HYPERBARIC OXYGEN; LABORATORY TEST; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; SALVAGE THERAPY; SOFT TISSUE INFECTION; STENOTROPHOMONAS MALTOPHILIA;

EID: 68349085611     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.3.367     Document Type: Letter

References (10)

1. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11 (1): 57-80. (Pubitemid 28046016)
2. Vartivarian SE, Papadakis KA, Palacios JA, Manning JT, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomoans maltophilia: a new spectrum. Ann Intern Med 1994; 121 (12): 969-973. (Pubitemid 24980425)
3. del Toro MD, Rodriguez-Bano J, Herrero M, et al. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine 2002; 81 (3): 228-239. (Pubitemid 34507209)
4. del Tora MD, Rodríguez-Baño J, Martínez- Martínez L etal. Epidemiology, clinical features and prognosis of infections due to Stenotrophomonas maltophilia. Enferm Infecc Microbiol Clin 2006; 24 (1): 4-9.
5. Muder RR. Optimizing therapy for Stenotrophomonas maltophilia. Semin Respir Crit Care Med 2007; 28 (6): 672-677.
6. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007; 26 (4): 229-237. (Pubitemid 46572029)
7. Shakil S, Akram M, AU, Khan. Tigecycline: a critical update. J Chemother 2008; 20 (4): 411-419.
8. Milatovic D, Schmitz FJ, Verhoef J, Huit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47 (1): 400-404. (Pubitemid 36070396)
9. Sader HS, Jones RN, Dowzicky MJ, Frirische TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52 (3): 203-208.
10. Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Picazo JJ. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50 (5) :758-759.